SCHEDULE: Vanguard Discloses 5.01% Stake in Collegium Pharma

Vanguard Capital Management has reported beneficial ownership of 5.01% of Collegium Pharmaceutical Inc.'s common stock as of June 30, 2026.

Summary

• Vanguard Capital Management, through various affiliates and managed accounts, now beneficially owns 1,625,821 shares of Collegium Pharmaceutical Inc. common stock.
• This holding represents 5.01% of the class of securities.
• The filing indicates that Vanguard has sole dispositive power over these shares and sole voting power over 244,560 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a standard disclosure of institutional ownership and does not inherently signal positive or negative performance for Collegium Pharmaceutical, but rather a significant investment by a major player.

Positives

• Vanguard's investment signifies confidence in Collegium Pharmaceutical's long-term prospects, potentially attracting further institutional interest.
• The 5.01% stake indicates a significant institutional holding, which can provide stability to the stock price.

Negatives

• The filing does not contain any negative financial or operational information about Collegium Pharmaceutical itself; it solely reports Vanguard's ownership stake.

Risks

• Potential for future changes in Vanguard's investment strategy could lead to significant buying or selling pressure on Collegium Pharmaceutical's stock.
• As a large institutional holder, Vanguard's voting power could influence corporate decisions, which may not always align with all shareholder interests.

Future Outlook

The filing does not contain forward-looking statements or guidance from Collegium Pharmaceutical. It solely reports Vanguard's ownership status.

Management Comments

• Vanguard Capital Management certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant institutional filings like this from major asset managers such as Vanguard often signal a stable or growing interest in the pharmaceutical sector, particularly in companies with established or developing product lines. This filing places Collegium Pharmaceutical within the scope of major investment portfolio management.

Stakeholder Impact

• Shareholders: The increased institutional ownership by a large, reputable firm like Vanguard may enhance investor confidence and potentially lead to greater stock liquidity.
• Management: Collegium Pharmaceutical's management will be aware of Vanguard's significant stake and potential influence on corporate governance and strategic decisions.
• Creditors: A stable institutional investor base can be viewed positively by creditors, suggesting a more stable financial outlook for the company.

Next Steps

• Vanguard will continue to monitor its investment in Collegium Pharmaceutical.
• Collegium Pharmaceutical will continue its business operations as usual, subject to potential influence from its significant institutional shareholders.

Key Dates

Keywords

Collegium Pharmaceutical, Vanguard Capital Management, Schedule 13G, Institutional Ownership, Common Stock, Beneficial Ownership, Securities Exchange Act